Yahoo
KOSDAQ - Delayed Quote KRW

PharmaResearch Co., Ltd. (214450.KQ)

212,000.00 -10,500.00 (-4.72%)
At close: October 30 at 3:30:06 PM GMT+9
Chart Range Bar
Loading chart for 214450.KQ
  • Previous Close 222,500.00
  • Open 219,000.00
  • Bid 212,000.00 x --
  • Ask 212,500.00 x --
  • Day's Range 208,000.00 - 222,000.00
  • 52 Week Range 208,000.00 - 561,000.00
  • Volume 81,676
  • Avg. Volume 135,377
  • Market Cap (intraday) 2.203T
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield 3,700.00 (1.66%)
  • Ex-Dividend Date Dec 29, 2025
  • 1y Target Est 486,133.34

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

pharmaresearch.co.kr

549

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

214450.KQ
47.39%
KOSPI Composite Index (^KS11)
35.99%

1-Year Return

214450.KQ
60.64%
KOSPI Composite Index (^KS11)
40.22%

3-Year Return

214450.KQ
81.81%
KOSPI Composite Index (^KS11)
148.02%

5-Year Return

214450.KQ
139.72%
KOSPI Composite Index (^KS11)
92.91%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 178.71B
Earnings 56.57B
Profit Margin 31.66%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50B
100B
150B
25.0%
30.0%
35.0%

Analyst Insights

View More

Analyst Price Targets

400,000.00
486,133.34 Average
212,000.00 Current
620,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.76%

  • Return on Assets (ttm)

    14.52%

  • Return on Equity (ttm)

    27.34%

  • Revenue (ttm)

    603.58B

  • Net Income Avi to Common (ttm)

    185.69B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    595.64B

  • Total Debt/Equity (mrq)

    27.90%

  • Levered Free Cash Flow (ttm)

    88.13B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: